Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM‐INSULIN randomized trial

AIMS: To investigate the efficacy and safety of alirocumab in participants with type 2 (T2D) or type 1 diabetes (T1D) treated with insulin who have elevated LDL cholesterol levels despite maximally tolerated statin therapy. METHODS: Participants at high cardiovascular risk with T2D (n = 441) or T1D...

Descripción completa

Detalles Bibliográficos
Autores principales: Leiter, Lawrence A., Cariou, Bertrand, Müller‐Wieland, Dirk, Colhoun, Helen M., Del Prato, Stefano, Tinahones, Francisco J., Ray, Kausik K., Bujas‐Bobanovic, Maja, Domenger, Catherine, Mandel, Jonas, Samuel, Rita, Henry, Robert R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698740/
https://www.ncbi.nlm.nih.gov/pubmed/28905478
http://dx.doi.org/10.1111/dom.13114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698740/
https://www.ncbi.nlm.nih.gov/pubmed/28905478
http://dx.doi.org/10.1111/dom.13114

Ejemplares similares